Intellia now has the data for No. 1 unanswered gene editing question: Does it last? Handheld ultrasound developer Butterfly Network stretches wings to 35% annual sales growth Editor's Corner: Fierce Biotech gets a fierce makeover Teladoc inks Amazon partnership for voice-activated virtual visits on Echo devices UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion CDC unveils new masking guidance based on community-level hospital capacity, severe infection risk FDA stresses the importance of regular checkups for aortic aneurysm implants Advantage Pfizer: GSK stops phase 3 trials of maternal RSV vaccine after seeing safety signal Dentsply Sirona brings digital dentistry to Google Cloud, launches 3D printing system Providers relieved CMS chose to overhaul Direct Contracting Model instead of canceling it Masimo’s brain-monitoring headset nabs FDA nod for use in kids Gemini CEO out the door as 80% of staff laid off, strategic review gets underway Chartis Group: Medicare Advantage enrollment grew by 2.3M for 2022 as for-profit plans see boost Surgical stapler maker Standard Bariatrics sews up $35M Featured Story | By Annalee Armstrong Intellia proved last year that gene editing can work in humans. But a lingering question was, for how long? Now, the biotech has the data to begin to answer that question. read more |
| |
|---|
|
Top Stories By Conor Hale With point-of-care ultrasound probes and subscription plans, the company raked in $62.6 million in 2021 compared to 2020's $46.3 million. read more By Annalee Armstrong Fierce Biotech is rolling out some big changes to help you get the news, analysis and insights you need in an easier-to-read format on our webpages. read more By Rebecca Torrence Amazon and Teladoc are teaming up to offer on-demand general medical care through Amazon's Alexa-enabled devices, available to U.S. customers 24/7. read more By Kyle LaHucik,Annalee Armstrong,Max Bayer,Eric Sagonowsky,Kevin Dunleavy CEOs at dozens of biotechs and investors from the industry's leading venture firms urged their global business counterparts to "disengage from Russian industry" over the weekend. read more By Dave Muoio The revamped approach is designed to predict whether a community's hospitals will be overrun with new COVID-19 cases within the next three to six weeks, CDC Director Rochelle Walensky, M.D., said Friday. Under the new model, CDC is no longer recommending universal public mask wearing indoors or in schools for the majority of U.S. counties. read more By Andrea Park According to the FDA’s letter, complications from endovascular aneurysm repair devices could be detected much earlier—potentially reducing long-term mortality rates—if patients and physicians stick to a regular checkup schedule. read more By Nick Paul Taylor Hopes of a quick fix for GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine woes are fading fast. Having voluntarily paused three maternal RSV vaccine clinical trials 10 days ago, GSK has now stopped enrollment and vaccination in the studies as it works to better understand the safety data. read more By Andrea Park Dental device maker Dentsply Sirona has a lot to smile about. This week, it unveiled two separate initiatives, both intended to support its efforts to bring dentistry thoroughly into the digital age. read more By Robert King Providers were relieved CMS decided to redesign the controversial Direct Contracting Model, but it remains unclear whether the changes will be enough to quell concerns from progressives. read more By Andrea Park The SedLine system was originally cleared by the FDA in 2004, with the agency’s permission to monitor brain activity while adult patients are under anesthesia. read more By Kyle LaHucik The CEO of Gemini Therapeutics exited Monday as the company laid off 80% of its staff, shifted priorities to a preclinical asset and began searching for a future. read more By Robert King A new study from the Chartis Group found that Medicare Advantage enrollment grew by 2.3 million, and now comprises 45% of total Medicare enrollment. read more By Andrea Park For Standard Bariatrics, a Cincinnati-based surgical devicemaker, collecting its series B financing was a multi-step affair. read more |
